Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Martin K. Gelbard"'
Autor:
Martin K. Gelbard, Joel Rosenbloom
Publikováno v:
Endocrinology, Diabetes & Metabolism, Vol 4, Iss 2, Pp n/a-n/a (2021)
Abstract Introduction Fibrosis is characterized by dysregulation and accumulation of extracellular matrix. Peyronie's disease and Dupuytren disease are fibroproliferative disorders of the tunica albuginea of the penis and fascia of the hand, respecti
Externí odkaz:
https://doaj.org/article/cd5ac8f6f4914f67a8a302a164bbcb83
Publikováno v:
Sexual Medicine Reviews. 10:409-420
Across many cultures, penis size has been associated with virility, and concerns about penile length are commonplace. Peyronie's disease (PD) is a known acquired cause of penile shortening.This paper describes the psychosocial impacts of penile lengt
Autor:
Martin K. Gelbard, Steven A. Mills
Publikováno v:
World Journal of Urology. 38:269-277
The introduction of collagenase Clostridium histolyticum (CCH) as the first and only FDA-approved non-surgical treatment for Peyronie’s disease (PD) has been an important step in its management. Our aim is to provide an overview of the historical o
Autor:
Martin K. Gelbard, Matthew Ziegelmann, Landon Trost, Wayne Jg Hellstrom, Laith Alzweri, Amanda S. J. Chung, Ramón Virasoro, Ashley Tapscott, Hoang Minh Tue Nguyen
Publikováno v:
Journal of Urology. 201:777-782
In a multi-institutional setting we studied the efficacy and safety outcomes at multiple high volume centers where collagenase Clostridium histolyticum is used to treat Peyronie's disease.We collected retrospective data on consecutive patients with P
Publikováno v:
Journal of drugs in dermatology : JDD. 19(9)
Clostridium collagenase histolyticum (CCH) is being evaluated in women as a cellulite treatment.To report preclinical safety and human pharmacokinetics (PK) and safety data for CCH.Across 3 PK studies, 41 women received 12 subcutaneous injections per
Publikováno v:
Urology. 146
Objective To examine the long-term (5-year) efficacy and safety of collagenase clostridium histolyticum (CCH) therapy in men with Peyronie's disease and varying degrees of plaque calcification. Materials and Methods CCH-treated adult men from the 12-
Autor:
Ramón Virasoro, Hoang Minh Tue Nguyen, Landon Trost, Ayad Yousif, Martin K. Gelbard, Matthew Ziegelmann, Amanda S. J. Chung, Wayne J.G. Hellstrom, Ashley H. Tapscott
Publikováno v:
Urology. 145
Objective To study, in a multi-institutional setting, the efficacy/safety outcomes in acute phase Peyronie's disease (PD) of multiple high-volume centers employing CCH to treat PD, which is defined as the abnormal formation of fibrous plaque(s) in th
Autor:
Michael McLane, Larry I. Lipshultz, Saji Vijayan, Genzhou Liu, Martin K. Gelbard, Yiqun Hu, Qinfang Xiang, Irwin Goldstein
Publikováno v:
The Journal of urology. 203(6)
We assessed the long-term safety and immunogenicity profile of collagenase clostridium histolyticum and characterized penile curvature deformity over time in patients previously treated for Peyronie's disease.This phase 4 study included men who recei
Publikováno v:
The Journal of Sexual Medicine. 17:S92-S93
Publikováno v:
Journal of Urology. 199